Grace Therapeutics (GRCE) vs SCYNEXIS (SCYX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Grace Therapeutics (GRCE) has outperformed SCYNEXIS (SCYX) over the past year, losing 32.0% versus a loss of 32.1%. Over five years, GRCE leads with a -80.5% price change compared with -90.5% for SCYX. Grace Therapeutics is the larger company by market cap ($42.9 million vs $42.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GRCE | SCYX |
|---|---|---|
| Share price | $2.04 | $4.22 |
| Market cap | $42.91M | $41.99M |
| 1-day change | -2.86% | -11.72% |
| YTD return | -41.04% | -16.53% |
| 1-year return | -32.00% | -32.11% |
| 5-year return | -80.46% | -90.53% |
| EPS (TTM) | $-1.17 | $-0.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.18 | $9.12 |
| 52-week low | $1.79 | $3.53 |
| Distance from 52-week high | -60.62% | -53.73% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +187.75% | +760.90% |
| Average volume | 171.87K | 274.80K |
| Shares outstanding | 21.04M | 9.95M |
| Employees | 5 | 18 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Grace Therapeutics
GRCE stock →Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
Healthcare · Biotechnology · 5 employees
About SCYNEXIS
SCYX stock →SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence.
Healthcare · Drug Manufacturers - Specialty & Generic · 18 employees
GRCE vs SCYX FAQ
Which is bigger, Grace Therapeutics or SCYNEXIS?
Grace Therapeutics (GRCE) is larger, with a market capitalization of $42.91M compared with $41.99M for SCYNEXIS (SCYX).
Which stock has performed better over the past year, GRCE or SCYX?
GRCE returned -32.00% over the past 12 months, compared with -32.11% for SCYX (price return, excluding dividends). Past performance does not predict future results.
Are Grace Therapeutics and SCYNEXIS in the same industry?
Both are in the Healthcare sector, but in different industries: Biotechnology for Grace Therapeutics and Drug Manufacturers - Specialty & Generic for SCYNEXIS.